Advertisement

Journal of Radiation Oncology

, Volume 8, Issue 3, pp 251–258 | Cite as

Thoracic radiotherapy for extensive-stage small-cell lung cancer: what is the optimal dose and timing?

  • Guler YavasEmail author
  • Cagdas Yavas
Review
  • 27 Downloads

Abstract

Small-cell lung cancer (SCLC) is a neuroendocrine tumor that represents about 12–20% of all lung cancers. Most of the SCLC patients present with extensive-stage (ES) disease. Primary therapy for ES-SCLC is 4–6 cycles of platinum-based chemotherapy (CT) followed by prophylactic cranial irradiation (PCI) in selected cases. Although the response rate to CT is approximately 60–70%, median survival times are very limited. The main problem of ES-SCLC patients after CT is intra-thoracic tumor recurrence since 75% of the patients had persisting intra-thoracic disease after CT, and approximately 90% of the patients had intra-thoracic progressive disease within the first year after diagnosis. Such high rate of intra-thoracic disease progression explains the need of local treatment in selected patients. There are three randomized studies and two meta-analyses evaluating the role of thoracic radiotherapy (TRT) in patients with ES-SCLC who responded to CT. Two of the randomized trials and one of the meta-analyses showed survival benefit of TRT. According to the results of relevant studies, the patients who responded to CT and have intra-thoracic residual disease after CT, who had limited metastatic sites (≤ 2), and who have good performance status and limited weight loss have more benefit from TRT. We need novel studies evaluating the optimal dose fractionation schedules, optimal timing of RT, impact of time interval between RT and CT, immunotherapy and RT combinations, and number of CT cycles.

Keywords

Small-cell lung cancer Extensive stage Thoracic radiotherapy, Radiation dose Survival 

Notes

Compliance with ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    van Meerbeeck JP, Fennell DA, De Ruysscher DK (2011) Small-cell lung cancer. Lancet 378:1741–1755CrossRefGoogle Scholar
  2. 2.
    Houston KA, Henly SJ, Li J, White MC, Richards TB (2014) Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009. Lung Cancer 86:22–28CrossRefGoogle Scholar
  3. 3.
    Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, ESMO Guidelines Working Group (2013) Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi99–v105CrossRefGoogle Scholar
  4. 4.
    Byers LA, Rudin CM (2015) Small cell lung cancer: where do we go from here? Cancer 121:664–672CrossRefGoogle Scholar
  5. 5.
    Zelen M (1973) Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 4:31/42Google Scholar
  6. 6.
    Stahel RA, Ginsberg R, Havemann K et al (1989) Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 5:119–126CrossRefGoogle Scholar
  7. 7.
    American Joint Committee on Cancer (2010) AJCC cancer staging handbook, 7th edn. Springer, New York, p 299323CrossRefGoogle Scholar
  8. 8.
    NCCN clinical practice guidelines in oncology: small cell lung cancer. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Version 1.2019 — October 10, 2018. Accessed: March 19, 2019
  9. 9.
    Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM (2013) Executive summary: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):7S–37SCrossRefGoogle Scholar
  10. 10.
    Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220–2229CrossRefGoogle Scholar
  11. 11.
    Jeremic B, Shibamoto Y, Nikolic N et al (1999) Role of radiation therapy in the combined-modality treatment of patients with extensive stage small-cell lung cancer: a randomized study. J Clin Oncol 17:2092–2099CrossRefGoogle Scholar
  12. 12.
    Slotman BJ, van Tinteren H, Praag JO et al (2015) Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomized controlled trial. Lancet 385:36–42CrossRefGoogle Scholar
  13. 13.
    Palma DA, Warner A, Louie AV, Senan S, Slotman B, Rodrigues GB (2016) Thoracic radiotherapy for extensive stage small-cell lung cancer: a meta-analysis. Clin Lung Cancer 17(4):239–244CrossRefGoogle Scholar
  14. 14.
    Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF et al (1994) Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer. J Clin Oncol 12:2022–2034CrossRefGoogle Scholar
  15. 15.
    Bunn PA Jr, Cohen MH, Ihde DC, Fossieck BE Jr, Matthews MJ, Minna JD (1977) Advances in small cell bronchogenic carcinoma: a commentary. Cancer Treat Rep 61:333–342PubMedGoogle Scholar
  16. 16.
    Beck LK, Kane MA, Bunn PA Jr (1988) Innovative and future approaches to small cell lung cancer treatment. Semin Oncol 15:300–314PubMedGoogle Scholar
  17. 17.
    Slotman BJ, FaivreFinn C, Kramer G et al (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357:664–672CrossRefGoogle Scholar
  18. 18.
    Jeremic B, Gomez-Caamano A, Dubinsky P, Cihoric N, Casas F, Filipovic N (2017) Radiation therapy in extensive stage small cell lung cancer. Front Oncol 7:169CrossRefGoogle Scholar
  19. 19.
    Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE et al (2017) Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extra-cranial irradiation for extensive disease small cell lung cancer (ED-SCLC): NRG oncology RTOG 0937. J Thorac Oncol 12(10):1561–1570CrossRefGoogle Scholar
  20. 20.
    Rathod S, Jeremic B, Dubey A, Giuliani M, Bashir B, Chowdhury A, Liang Y, Pereira S, Agarwal J, Koul R (2019) Role of thoracic consolidation radiation in extensive stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Eur J Cancer 110:110–119CrossRefGoogle Scholar
  21. 21.
    Slotman BJ, Faivre-Finn C, van Tinteren H, Keijser A, Praag J, Knegjens J, Hatton M et al (2017) Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: a secondary analysis of the Phase III CREST trial. Lung Cancer 108:150–153CrossRefGoogle Scholar
  22. 22.
    Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, Sharouni El SY, Hatton M et al (2015) Radiotherapy for extensive stage small-cell lung cancer – authors’ reply. Lancet 385:1292–1293CrossRefGoogle Scholar
  23. 23.
    Slotman BJ, van Tinteren H (2015) Which patients with extensive stage small-cell lung cancer should and should not receive thoracic radiotherapy. Transl Lung Cancer Res 4:292–294PubMedPubMedCentralGoogle Scholar
  24. 24.
    Xu LM, Cheng C, Kang M et al (2017) Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer. Sci Rep 7(1):9255CrossRefGoogle Scholar
  25. 25.
    Li-Ming X, Zhao LJ, Simone CB 2nd, Cheng C, Kang M, Wang X, Gong LL, Pang QS, Wang J, Yuan ZY, Wang P (2017) Receipt of thoracic radiation therapy and radiotherapy dose are correlated with outcomes in a retrospective study of three hundred and six patients with extensive stage small-cell lung cancer. Radiother Oncol 125(2):331–337CrossRefGoogle Scholar
  26. 26.
    Hasan S, Renz P, Turrisi A, Colonias A, Finley G, Wegner RE (2018) Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): a National Cancer Database (NCDB) propensity-matched analysis. Lung Cancer 124:283–290CrossRefGoogle Scholar
  27. 27.
    Singer L, Yom SS (2015) Consolidative radiation therapy for extensive stage small cell lung cancer. Transl Lung Cancer Res 4(3):211–214PubMedPubMedCentralGoogle Scholar
  28. 28.
    Kalemkerian GP, Loo BW, Akerley W et al. NCCN guidelines version 1.2019 Panel Members Small Cell Lung Cancer Charles Florsheim Patient Advocate. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed April 21, 2019
  29. 29.
    Mitin T, Jain A, Degnin C, Chen Y, Henderson M, Thomas CR Jr (2016) Current patterns of care for patients with extensive stage small cell lung cancer: Survey of US radiation oncologists on their recommendations regarding thoracic consolidation radiotherapy. Lung Cancer 100:85–89CrossRefGoogle Scholar
  30. 30.
    De Ruysscher D, Pijls-Johannesma M, Bentzen SM, Minken A, Wanders R, Lutgens L, Hochstenbag M, Boersma L, Wouters B, Lammering G, Vansteenkiste J (2006) Lambin P (2006) Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24(7):1057–1063CrossRefGoogle Scholar
  31. 31.
    Overgaard J, Hansen HS, Specht L et al (2003) Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362:933–940CrossRefGoogle Scholar
  32. 32.
    Bernier J, Bentzen SM (2003) Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 39:560–571CrossRefGoogle Scholar
  33. 33.
    Bentzen SM (2003) Repopulation in radiation oncology: perspectives of clinical research. Int J Radiat Biol 79:581–585CrossRefGoogle Scholar
  34. 34.
    Davis AJ, Tannock IF (2000) Repopulation of tumor cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 1:86–93CrossRefGoogle Scholar
  35. 35.
    Jackman DM, Johnson BE (2005) Small-cell lung cancer. Lancet 366(9494):1385–1396CrossRefGoogle Scholar
  36. 36.
    De Ruysscher D, Vansteenkiste J (2000) Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects. Radiother Oncol 55:1–9CrossRefGoogle Scholar
  37. 37.
    Pijls-Johannesma MCG, De Ruysscher DKM, Rutten I et al (2005) Early versus late chest radiotherapy for limited stage small cell lung cancer. In: The Cochrane Library (issue 1). Wiley, Chichester, p CD004700Google Scholar
  38. 38.
    Fried DB, Morris DE, Poole C et al (2004) Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22:4837–4845CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Radiation Oncology, Faculty of MedicineSelcuk UniversityKonyaTurkey

Personalised recommendations